The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
Male or female patients, ages 18 years or older,
AML diagnosed per ELN criteria1 which has been treated with at least two lines of therapy,
which is relapsed (after previously complete remission, CR, CRh or CRi), or
refractory (failed to achieve complete remission) to the last treatment*, *Primary refractory patients should have received at least two cycles of induction treatment
Leukemic blast count of >20,000/μl. If the blast count can be maintained below the threshold with hydroxyurea, the patient would be eligible.
Patients with extramedullary only AML.
Patients that are candidates for hematopoietic stem cell transplant.
Patients that are eligible to receive an approved targeted therapy.
BlueSphere Bio, Inc
Lead sponsor